Key result
Increasing PAF-AH activity was independently associated with angiographic coronary artery disease (OR 1.39; 95% CI 1.26 to 1.54; P<0.001) after adjusting for cardiovascular drug use.
Why the study?
Is platelet-activating factor acetylhydrolase (PAF-AH) activity associated with angiographic coronary artery disease independently of systemic inflammation and other risk factors?
Case-Control (n=3,148)
Is platelet-activating factor acetylhydrolase (PAF-AH) activity associated with angiographic coronary artery disease independently of systemic inflammation and other risk factors?
Effect estimate: OR 1.39 (95% CI 1.26 to 1.54)
p-value: p=<0.001
PAF-AH activity is independently associated with angiographic coronary artery disease, complementary to sCRP and independent of LDL cholesterol, though it is affected by several cardiovascular medications.
No takes yet. Share an insight, caveat, or question.
May complement CRP for CAD risk assessment; leaves open causality and whether modulating PAF-AH alters outcomes.
Winkler et al. (2005) conducted a case-control in Coronary artery disease (n=3,148). Platelet-activating factor acetylhydrolase (PAF-AH) activity vs. Control subjects was evaluated on Angiographic coronary artery disease (OR 1.39, 95% CI 1.26 to 1.54, p=<0.001). Increasing PAF-AH activity was independently associated with angiographic coronary artery disease (OR 1.39; 95% CI 1.26 to 1.54; P<0.001) after adjusting for cardiovascular drug use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: